IL278898B2 - Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity - Google Patents

Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity

Info

Publication number
IL278898B2
IL278898B2 IL278898A IL27889820A IL278898B2 IL 278898 B2 IL278898 B2 IL 278898B2 IL 278898 A IL278898 A IL 278898A IL 27889820 A IL27889820 A IL 27889820A IL 278898 B2 IL278898 B2 IL 278898B2
Authority
IL
Israel
Prior art keywords
immunogenic product
immunogenic
muil
crm197
allergic
Prior art date
Application number
IL278898A
Other languages
English (en)
Hebrew (he)
Other versions
IL278898A (en
IL278898B1 (en
Inventor
Grouard-Vogel Geraldine
Conde Garcia Eva
Bertrand Romain
Caillot Noemie
Reber Laurent
Bruhns Pierre
Serra Vincent
Original Assignee
Inst Nat Sante Rech Med
Pasteur Institut
Neovacs
Geraldine Grouard Vogel
Conde Garcia Eva
Bertrand Romain
Caillot Noemie
Reber Laurent
Bruhns Pierre
Serra Vincent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Pasteur Institut, Neovacs, Geraldine Grouard Vogel, Conde Garcia Eva, Bertrand Romain, Caillot Noemie, Reber Laurent, Bruhns Pierre, Serra Vincent filed Critical Inst Nat Sante Rech Med
Publication of IL278898A publication Critical patent/IL278898A/en
Publication of IL278898B1 publication Critical patent/IL278898B1/en
Publication of IL278898B2 publication Critical patent/IL278898B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL278898A 2018-05-29 2019-05-29 Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity IL278898B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862677290P 2018-05-29 2018-05-29
EP18305651.4A EP3574915A1 (en) 2018-05-29 2018-05-29 Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
PCT/EP2019/050154 WO2019228674A1 (en) 2018-05-29 2019-01-04 Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il-13 expression or activity
PCT/EP2019/064025 WO2019229153A2 (en) 2018-05-29 2019-05-29 Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity

Publications (3)

Publication Number Publication Date
IL278898A IL278898A (en) 2021-01-31
IL278898B1 IL278898B1 (en) 2024-02-01
IL278898B2 true IL278898B2 (en) 2024-06-01

Family

ID=62631036

Family Applications (2)

Application Number Title Priority Date Filing Date
IL278898A IL278898B2 (en) 2018-05-29 2019-05-29 Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
IL309932A IL309932A (en) 2018-05-29 2019-05-29 Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL309932A IL309932A (en) 2018-05-29 2019-05-29 Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity

Country Status (15)

Country Link
US (2) US12059457B2 (https=)
EP (3) EP3574915A1 (https=)
JP (2) JP7291729B2 (https=)
KR (2) KR102871378B1 (https=)
CN (1) CN112423784B (https=)
AU (2) AU2019276173B2 (https=)
BR (1) BR112020024308A2 (https=)
CA (1) CA3101702A1 (https=)
CU (1) CU20200091A7 (https=)
IL (2) IL278898B2 (https=)
MA (1) MA52748A (https=)
MX (2) MX421649B (https=)
SG (1) SG11202011528UA (https=)
WO (2) WO2019228674A1 (https=)
ZA (1) ZA202007264B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7641912B2 (ja) 2019-04-19 2025-03-07 シナーキン・ファーマ・ベスローテン・フエンノートシャップ Ｉｌ１３を含む融合タンパク質
EP3845556A1 (fr) * 2019-12-31 2021-07-07 Peptinov SAS Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l interleukine-6
WO2023021195A1 (en) * 2021-08-20 2023-02-23 Neovacs mRNA VACCINES COMPRISING IL-4 AND/OR IL-13 RNA AND USES THEREOF

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US646A (en) 1838-03-21 Improvement in furnaces for smelting iron with anthracite
US6207A (en) 1849-03-20 Improved spriing snap-hook
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US5769047A (en) 1991-12-23 1998-06-23 Zoche; Michael Engine with oil separator
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
ATE378066T1 (de) 1998-09-30 2007-11-15 Wyeth Corp Mutiertes cholera holotoxin als hilfsmittel
KR100898648B1 (ko) 2001-06-07 2009-05-22 와이어쓰 홀딩스 코포레이션 보조제로서 콜레라 홀로톡신의 돌연변이체 형태
CA2449670A1 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
WO2003040164A2 (en) 2001-11-07 2003-05-15 Cytos Biotechnology Ag Antigen arrays presenting il-5, il-3 or eotaxin for treatment of allergic eosinophilic diseases
JP2006503017A (ja) 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド Ｉｌ−１３要素及びｔ細胞エピトープを含む免疫原組成物並びにその治療上の使用
JP2006503018A (ja) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド ワクチン
EP1947116B1 (en) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
CA2562642A1 (en) * 2004-04-13 2005-11-03 Alza Corporation Apparatus and method for transdermal delivery of multiple vaccines
US20070224205A1 (en) * 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
CN100558747C (zh) * 2006-04-06 2009-11-11 海南天源康泽医药科技有限公司 以白喉毒素突变体crm197为载体的免疫原及其制备方法与应用
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
MX2013011201A (es) 2011-03-29 2013-12-16 Immunogen Inc Proceso para la elaboracion de conjugados de mejor homogeneidad.
CA2832260C (en) * 2011-04-07 2021-06-22 Neovacs Method for treating ifnalpha related conditions
CA2835018C (en) * 2011-05-04 2020-04-21 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
CN102807621B (zh) * 2011-06-01 2016-04-13 厦门大学 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
EP2659906A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
DE202013011988U1 (de) 2012-05-15 2015-04-01 Rajesh Shah Entzündungshemmende Rezeptur
PL2668959T3 (pl) * 2012-05-31 2015-04-30 Innavirvax Związki immunogenne zawierające peptyd HIV gp41 sprzężony z białkiem nośnikowym CRM197
AR101455A1 (es) * 2014-08-05 2016-12-21 Glaxosmithkline Biologicals Sa Molécula portadora
CN109890408A (zh) * 2016-05-27 2019-06-14 埃特彼塞斯公司 新表位疫苗组合物及其使用方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DIEGO BAGNASCO ET AL:, A CRITICAL EVALUATION OF ANTI-IL-13 AND ANTI-IL-4 STRATEGIES IN SEVERE ASTHMA, 1 January 2016 (2016-01-01) *
LE BUANEC ET AL:, CONTROL OF ALLERGIC REACTIONS IN MICE BY AN ACTIVE ANTI-MURINE IL-4 IMMUNIZATION, 27 September 2007 (2007-09-27) *
MA ET AL:, A POTENTIAL IMMUNOTHERAPY APPROACH: MUCOSAL IMMUNIZATION WITH AN IL-13 PEPTIDE-BASED VIRUS-LIKE PARTICLE VACCINE IN A MOUSE ASTHMA MODEL, 26 October 2007 (2007-10-26) *
YANBING MA:, SUSTAINED SUPPRESSION OF IL-13 BY A VACCINE ATTENUATES AIRWAY INFLAMMATION AND REMODELING IN MICE, 1 January 2013 (2013-01-01) *
ZAGURY D ET AL:, ACTIVE VERSUS PASSIVE ANTI-CYTOKINE AND ANTIBODY THERAPY AGAINST CYTOKINE-ASSOCIATED CHRONIC DISEASES, 1 January 2003 (2003-01-01) *
ZHANG H L ET AL:, A NOVEL COMBINED CONJUGATE VACCINE: ENHANCED IMMUNOGENICITY OF BFGF WITH CRM197 AS A CARRIER PROTEIN, 1 September 2011 (2011-09-01) *

Also Published As

Publication number Publication date
CU20200091A7 (es) 2021-07-02
AU2019276173A1 (en) 2020-12-17
KR20250156179A (ko) 2025-10-31
EP3801603A2 (en) 2021-04-14
JP2023110045A (ja) 2023-08-08
MA52748A (fr) 2021-06-02
WO2019229153A2 (en) 2019-12-05
US12059457B2 (en) 2024-08-13
EP4144366A1 (en) 2023-03-08
MX2024012944A (es) 2024-12-06
MX2020012925A (es) 2021-08-11
CN112423784B (zh) 2024-09-20
AU2019276173B2 (en) 2025-10-23
WO2019228674A1 (en) 2019-12-05
US20210205427A1 (en) 2021-07-08
US20250025541A1 (en) 2025-01-23
IL278898A (en) 2021-01-31
ZA202007264B (en) 2025-04-30
CA3101702A1 (en) 2019-12-05
JP2021525726A (ja) 2021-09-27
KR20210022571A (ko) 2021-03-03
IL278898B1 (en) 2024-02-01
IL309932A (en) 2024-03-01
JP7291729B2 (ja) 2023-06-15
CN112423784A (zh) 2021-02-26
EP3574915A1 (en) 2019-12-04
BR112020024308A2 (pt) 2021-02-23
SG11202011528UA (en) 2020-12-30
KR102871378B1 (ko) 2025-10-16
AU2025204082A1 (en) 2025-06-26
WO2019229153A3 (en) 2020-02-20
MX421649B (es) 2025-03-14

Similar Documents

Publication Publication Date Title
US20250025541A1 (en) Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
Dorofeeva et al. Past, present, and future of allergen immunotherapy vaccines
Palomares et al. Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells
US20120076808A1 (en) Combined antigen and dna vaccine for preventing and treating autoimmune diseases
Kim et al. Mycobacterium tuberculosis PE27 activates dendritic cells and contributes to Th1-polarized memory immune responses during in vivo infection
WO2013044419A1 (en) Combined facilitator, antigen and dna vaccine for preventing and treating autoimmune diseases
Cravens et al. Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet
RU2809548C2 (ru) Иммуногенный продукт, содержащий il-4 и/или il-13 для лечения нарушений, ассоциированных с аберрантной экспрессией или активностью il-4 и/или il-13
HK40089589A (en) Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
US20230364232A1 (en) IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS
Hosoi et al. Memory Th1 cells augment tumor-specific CTL following transcutaneous peptide immunization
TW202245834A (zh) 基於控制細胞性免疫之新穎方法之新穎治療及預防
CN116615230A (zh) 用于治疗IgE介导的炎性病症的包含IgE片段的免疫原性产品
Akdis Immunologic responses to sublingual allergen immunotherapy
WO2018094570A1 (zh) 多肽及其应用
Andersson Novel allergen preparations for use in allergen-specific immunotherapy
Thorburn A Streptococcus pneumoniae-based immunoregulatory therapy for asthma
Thunberg Novel treatment strategies and regulation of IgE-mediated allergic disease.